Genomic Alterations Identification and Resistance Mechanisms Exploration of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study.
Frontiers In Oncology
Shen, Fangfang F; Liang, Naixin N; Fan, Zaiwen Z; Zhao, Min M; Kang, Jing J; Wang, Xifang X; Hu, Qun Q; Mu, Yongping Y; Wang, Kai K; Yuan, Mingming M; Chen, Rongrong R; Guo, Wei W; Dong, Guilan G; Zhao, Jun J; Bai, Jun J
A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses.
Cancers
Koopman, Bart B; Cajiao Garcia, Betzabel N BN; Kuijpers, Chantal C H J CCHJ; Damhuis, Ronald A M RAM; van der Wekken, Anthonie J AJ; Groen, Harry J M HJM; Schuuring, Ed E; Willems, Stefan M SM; van Kempen, Léon C LC
Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.
Plos One
Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS
Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.
British Journal Of Cancer
Kuiper, J L JL; Hashemi, S M S SM; Thunnissen, E E; Snijders, P J F PJ; Grünberg, K K; Bloemena, E E; Sie, D D; Postmus, P E PE; Heideman, D A M DA; Smit, E F EF
Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Cell Death & Disease
Sette, G G; Salvati, V V; Mottolese, M M; Visca, P P; Gallo, E E; Fecchi, K K; Pilozzi, E E; Duranti, E E; Policicchio, E E; Tartaglia, M M; Milella, M M; De Maria, R R; Eramo, A A
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Oncotarget
Wheler, Jennifer J; Falchook, Gerald G; Tsimberidou, Apostolia M AM; Hong, David D; Naing, Aung A; Piha-Paul, Sarina S; Chen, Su S SS; Heymach, John J; Fu, Siqing S; Stephen, Bettzy B; Fok, Jansina Y JY; Janku, Filip F; Kurzrock, Razelle R
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer.
Oncotarget
Falchook, Gerald S GS; Naing, Aung A; Hong, David S DS; Zinner, Ralph R; Fu, Siqing S; Piha-Paul, Sarina A SA; Tsimberidou, Apostolia M AM; Morgan-Linnell, Sonia K SK; Jiang, Yunfang Y; Bastida, Christel C; Wheler, Jennifer J JJ; Kurzrock, Razelle R
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Heon, Stephanie S; Yeap, Beow Y BY; Lindeman, Neal I NI; Joshi, Victoria A VA; Butaney, Mohit M; Britt, Gregory J GJ; Costa, Daniel B DB; Rabin, Michael S MS; Jackman, David M DM; Johnson, Bruce E BE
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Heon, Stephanie S; Yeap, Beow Y BY; Britt, Gregory J GJ; Costa, Daniel B DB; Rabin, Michael S MS; Jackman, David M DM; Johnson, Bruce E BE
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Jackman, David M DM; Miller, Vincent A VA; Cioffredi, Leigh-Anne LA; Yeap, Beow Y BY; Jänne, Pasi A PA; Riely, Gregory J GJ; Ruiz, Marielle Gallegos MG; Giaccone, Giuseppe G; Sequist, Lecia V LV; Johnson, Bruce E BE